No Prescription |
 |
 | ||
|
Somac Protonix |
|
| ||
No Prescription » Prescription Drugs 15 » Somac Protonix IndicationsI. For the symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: 1.Duodenal ulcer 2.Gastric ulcer 3.Gastro-oesophageal reflux disease (GORD) - For the treatment of mild reflux disease and associated symptoms (e.g. heartburn acid regurgitation pain on swallowing) - Reflux oesophagitis 4.Zollinger-Ellison Syndrome II. Eradication of Helicobacter pylori (hereinafter referred to as H. pylori) in combination with -clarithromycin and amoxycillin or -clarithromycin and metronidazole or -amoxycillin and metronidazoleIII. Prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in patients at risk with a need for continuous NSAID treatment. Dosage and AdministrationDuodenal UlcerThe recommended oral dosage is one gastro-resistant tablet SOMAC 40mg per day. A duodenal ulcer generally heals within 2 weeks. If a 2-week period of treatment is not sufficient healing will be achieved in almost all cases within a further 2 weeks.Gastric UlcerThe recommended oral dosage is one gastro-resistant tablet SOMAC 40mg per day.A 4-week period is usually required for the treatment of gastric ulcers. If this is not sufficient healing will usually be achieved within a further 4 weeks.GORDFor mild reflux disease and the associated symptoms the recommended dosage is one SOMAC 20mg tablet per day. Symptom relief is generally accomplished within 2-4 weeks. If symptom control has not been achieved after four weeks treatment with SOMAC 20mg tablets daily further investigation is recommended.For treatment of reflux oesophagitis the recommended oral dosage is one SOMAC 40mg tablet per day. A 4-week period is usually required for treatment of reflux oesophagitis however if this is not sufficient healing will usually be achieved within a further 4 weeks.Zollinger-Ellison SyndromeThe recommended oral dosage is one gastro-resistant tablet SOMAC 40mg per day.Prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in patients at risk with a need for continuous NSAID treatment.The recommended oral dosage is one gastro-resistant tablet SOMAC 20mg per day.MaintenanceDuodenal and Gastric Ulcer and Zollinger-Ellison Syndrome:For long-term management a maintenance dose of one gastro-resistant tablet SOMAC 40mg per day is recommended.Reflux OesophagitisA maintenance dose of one SOMAC 20mg tablet per day is recommended increasing to 40mg per day if relapse occurs. After healing of the relapse the dosage can be reduced again to 20mg SOMAC.Experience with long-term administration in man over several years is available in a limited number of patients. Therefore long-term treatment exceeding 1 year may be considered after careful evaluation of the risk benefit ratio. Patients should then be kept under regular surveillance.Use in childrenThere are no data currently available on the use of pantoprazole in children.Use in the elderlyThe daily dose of 20 mg or 40mg can be given. An exception is combination therapy for eradication of H. pylori where also elderly patients should receive the usual pantoprazole dose (2 x 40mg/day) during 1-week treatment.Impaired Renal FunctionThe daily dose of 20mg or 40mg can be given.Impaired Liver FunctionIn patients with severe liver impairment the dose has to be reduced to 20mg pantoprazole per day. Buy Somac Protonix and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Somac Protonix: Product Type: Prescription Drugs 15 Somac ( Protonix Generic Pantoprazole ) Somac (Protonix Generic Pantoprazole) Protonix Generic Pantoprazole 20mg Protonix Generic Pantoprazole Somac
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
